Hannah Morgan

ESTP Congress
,

Description

Dr. Hannah Morgan is a Senior Principal Scientist at Novartis. Prior to joining Novartis she received her PhD in molecular and cellular neuroscience from University College London in 2009. In her current position in the translational immunology group in preclinical safety, she specializes in the in vitro assessment of both the immunogenicity potential for biotherapeutics as well as the prediction and mechanistic understanding of immune-related toxicities for multiple modalities. Additionally, she is a member of a number of industry/academic consortia (e.g. HESI-ITC, ImSAVAR) working collaboratively to develop, validate and improve models for the assessment of immune-related adverse effects.